Skip to search formSkip to main contentSkip to account menu

Geroxalen

Known as: Methoxsalen Sanofi-Synthelabo Brand, Sanofi Synthelabo Brand of Methoxsalen, Sanofi-Synthelabo Brand of Methoxsalen 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Methoxsalen

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design (P3.2-091)
Objective: To assess ocrelizumab efficacy on upper limb function in more disabled/older patients with primary progressive… 
Review
2018
Review
2018
Cochrane examines whether lead author of HPV review had undeclared conflicts of interest
The Cochrane Collaboration has asked its expert committee on financial links to consider whether the lead author of the review… 
2016
2016
Mentoring jako wsparcie rozwoju kadry menedżerskiej firmy Sanofi Polska
2014
2014
Tropical diseases. Dengue vaccine trial poses public health quandary.
The first large efficacy trial of a vaccine for the tropical disease dengue has returned puzzling results. The vaccine, developed… 
2011
2011
Persistence of Immunity Following a Booster Dose of Haemophilus Influenzae Type B-Meningococcal Serogroup C Glycoconjugate Vaccine: Follow-up of a Randomized Controlled Trial
Background: Antibodies against Haemophilus influenzae type b (Hib) and serogroup C Neisseria meningitidis (MenC) wane after early… 
2009
2009
Treatments for nicotine addiction should be a top priority
2009
2009
Recurrent miscarriage syndrome treated with acupuncture and an allergy elimination/desensitization technique.
In December, 2001, a 33-year-old female—“SC”—gravida 2, para 0-0-2-0, came in with the chief complaints of repeated miscarriage… 
Review
2006
Review
2006
Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent.
sanofi-aventis (formerly Sanofi-Synthelabo) is developing the oral class III anti-arrhythmic agent dronedarone (Multaq) for the… 
Review
2004
Review
2004
Developments in combination chemotherapy for colorectal cancer
In the last 5 years, major advances have occurred in the treatment of colorectal cancer. Following a period of over 30 years in… 
2002
2002
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs
The physical compatibility of oxaliplatin (Eloxatin, Sanofi-Synthelabo, Malvern, PA) with 58 selected other drugs during… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)